Neurocrine Biosciences, Inc. (BIT:1NBIX)

Market Cap	10.90B
Revenue (ttm)	2.23B
Net Income (ttm)	282.93M
Shares Out	n/a
EPS (ttm)	2.74
PE Ratio	38.51
Forward PE	15.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	107.70
Previous Close	107.70
Day's Range	107.70 - 107.70
52-Week Range	106.35 - 107.70
Beta	n/a
RSI	n/a
Earnings Date	Jul 31, 2025

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,800
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1NBIX

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Financial numbers in USD